Cerebrolysin
Neuropeptide Preparation | Neurological Recovery
On this page
What is Cerebrolysin?
Cerebrolysin is a standardized mixture of small peptides and amino acids purified from porcine (pig) brain tissue, studied for possible neuroprotective and neurotrophic effects. It has been researched most in the context of stroke recovery, traumatic brain injury, and vascular dementia, with a mixed record across published clinical trials. It is not FDA-approved and is discussed here for laboratory and research reference only, not for human treatment.
Key terms:
Cerebrolysin is a neuropeptide preparation.
Cerebrolysin is a standardized mix of small peptides and amino acids made from purified pig (porcine) brain proteins. Research describes it as neurotrophic (supporting nerve-cell growth) and neuroprotective. It has been studied for stroke recovery, traumatic brain injury, and cognitive effects.
Key research areas
- Direct brain delivery
- Standardized dosing
- Extensive clinical evidence
- Ready-to-use formulation
Researched dosing
This table reflects the dose volumes and schedules used in published clinical trials of cerebrolysin, presented as research-methodology reference, not personal usage instructions.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Low-volume IV protocols | Up to 10 mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular studies (lower doses) | Up to 5 mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute stroke studies | 20-50 mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic brain injury studies | 20-50 mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's disease studies | 10-30 mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular dementia studies | 10-30 mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Commonly cycled 4 weeks on, 4+ weeks off.
How it works
At the cell level, cerebrolysin research looks at how its mix of small peptides and amino acids may support neuron survival and signaling in the brain, similar in concept to natural neurotrophic factors like BDNF — the terms below are just the names for those pathways.
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors
Pharmacokinetics
This chart shows how a research dose of cerebrolysin is absorbed and cleared in the reported data — it clears quickly, within a few hours, which is part of why clinical protocols use daily dosing.
- Peak
- 0.5 hr
- Half-life
- 1 hrs
- Cleared
- ~5 hrs
EVER Pharma data
Research applications
This section lists the research areas — stroke recovery, brain injury, and dementia — that scientists have studied for cerebrolysin in clinical trials, with results described in the literature as mixed; it's a summary of what's been investigated, not a diagnosis or treatment claim for any condition.
Cognitive
Meta-analyses show modest cognitive improvements for Alzheimer's Disease, though clinical significance remains debated in medical literature. Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements for Vascular Dementia with well-documented protocols. Large meta-analysis shows significant NIHSS improvements for Post-Stroke Cognitive Recovery, though other studies found no functional benefit.
Neuroprotection
Neurotrophic and neuroprotective properties through bioactive peptides and amino acids derived from purified porcine brain proteins.
Recovery
Supports neurological recovery in stroke and traumatic brain injury through enhanced brain penetration of neuropeptides and neurotrophic factors.
Dosage reference
- Doses used in research
- Studies used 20–50 mL in acute protocols and 10–30 mL in chronic protocols.
- Frequency in studies
- Once daily (acute) or 5 days weekly (chronic)
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Acute: 24-72 hours; Cognitive: 2-4 weeks; Full recovery: 4-12 weeks
- Storage
- Room temperature ≤25°C, protect from light, never freeze
- Cycle length
- Acute: 7-30 days; Chronic: 4 weeks (2-4 cycles yearly)
- Break between cycles
- Cycles separated by 1-3 months for chronic conditions
Interactions
This list shows which other cognitive- and neurological-research compounds are studied alongside cerebrolysin in the literature.
Reconstitution & storage
Cerebrolysin ships pre-mixed in sealed ampoules rather than as a powder to reconstitute — this section covers how a research dose is drawn and handled right before use.
- Break ampoule and extract Cerebrolysin contents immediately before use
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature ≤25°C, use within As per manufacturer dating, never freeze
Reconstituted: 2-6°C, use within Use within 15 minutes of dilution for infusion
Quality indicators
These are the checks researchers use to confirm a cerebrolysin sample is authentic and hasn't degraded — sourcing from an authorized distributor and checking solution clarity are the main reference points.
Clear amber solution from reputable source - Cerebrolysin should be clear amber colored without particles. Ensure sourcing from authorized EVER Pharma distributors
Room temperature storage ≤25°C as specified - Store at room temperature per official prescribing information, never freeze
Protected from light - Stored in original carton to protect from light exposure
Clinical evidence awareness - Be aware that research shows mixed results - some large studies positive, others neutral
Research quality considerations - Some published studies have been retracted due to research misconduct - rely on independent meta-analyses
Frozen product or improper storage - Never freeze Cerebrolysin - freezing damages peptide structure and renders product ineffective
Mixing with incompatible solutions - Do not mix with amino acid solutions, vitamins, or cardiovascular medications per official guidelines
What to expect
This timeline summarizes what the clinical-trial literature reports at each study stage — research context for comparing studies, not a personal-results promise, especially given the mixed results reported across different trials.
Initial neuroprotective effects, possible mild side effects (dizziness, agitation)
Neurological improvements become apparent, cognitive function may begin to improve
Continued recovery, motor function improvements in stroke/TBI patients
Sustained benefits, cognitive enhancement plateaus in chronic conditions
Safety notes
This section covers cerebrolysin's regulatory status and handling notes drawn from clinical literature and official prescribing information used in other countries — reference context for research, not medical advice.
- Contraindicated in epilepsy and severe renal insufficiency per official prescribing information
- Use disposable one-way infusion sets to guarantee sterility
- Not approved in USA but used clinically in over 50 countries worldwide
- Research integrity concerns have been raised about some published studies
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant improvements in neurological scores
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores
First randomized trial in SAH patients showing promising results with 76% vs 48% favorable outcomes